0000000000973059

AUTHOR

Lloyd E. Damon

showing 1 related works from this author

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

2003

The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy. The median age of the patients was 57 years (range 22-67). In all, 268 patients received peripheral blood stem cells, and 47 patients received autologous bone marrow. After a median follow-up of 57 months (range 10-125), three cases of secondary AML (sAML) were observed, resulting in a cumulative incidence of 0.94%. One case of sAML developed 18 months after HDCT (FAB M3) The karyotype was trans…

OncologyTransplantation Conditioningmedicine.medical_treatmentAutologous stem-cell transplantationLeukemia Promyelocytic Acutehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMelphalanBone Marrow TransplantationLeukemia Radiation-InducedAcute leukemiaIncidenceCytarabineNeoplasms Second PrimaryHematologyMiddle AgedCombined Modality TherapyLeukemia MyeloidLymphatic MetastasisAcute DiseaseFemalemedicine.drugAdultmedicine.medical_specialtyPaclitaxelBreast NeoplasmsTransplantation AutologousLeukemia Myelomonocytic AcuteBreast cancerInternal medicinemedicineAdjuvant therapyHumansCyclophosphamideAgedEpirubicinTransplantationChemotherapyMitoxantronePeripheral Blood Stem Cell Transplantationbusiness.industryDaunorubicinmedicine.diseaseSurgeryRadiation therapyTransplantationDoxorubicinRadiotherapy AdjuvantMitoxantronebusinessThiotepaBone marrow transplantation
researchProduct